-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, Hisun Pharmaceutical issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for tigecycline for injection approved and issued by the State Food and Drug Administration.
Tigecycline for injection is mainly suitable for the treatment of infections caused by sensitive strains of specific bacteria in patients over 18 years of age under the following conditions: complicated intra-abdominal infections, complicated skin and skin soft tissue infections, and community-acquired bacterial pneumonia.
According to statistics, the global sales of tigecycline for injection in 2019 are approximately US$358,484,100, of which China’s sales are approximately US$177,563,900; the global sales in 2020 are approximately US$343.
Hisun Pharmaceutical's sales revenue of tigecycline for injection in 2020 was 205,995,900 yuan.